Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05914324

Outpatient Pediatric Pulse Oximeters in Africa

The primary objective of this clinical trial is to evaluate the performance of three pulse oximeters during outpatient care within Cape Town, South Africa. This objective will be achieved through generating evidence on how, why, for whom, to what extent and at what cost can paediatric pulse oximetry devices improve the management of hypoxemic children. This will be done with two inter-linked studies:

* Aim 1: Determine the impact of two novel paediatric pulse oximeter devices on the correct management of hypoxaemia. * Aim 2: Describe the burden of hypoxaemia and risks for mortality amongst children presenting with acute respiratory infections in a low-resource setting in Cape Town.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

0 month–23 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Desmond Tutu TB Centre

Cape Town, Western Cape, 7505, South Africa

About this study

Background:

Lower respiratory tract infections (LRI) remain the leading infectious cause of death globally for children younger than five years.1 Alarmingly, >50% of LRI deaths occurred in low and middle-income countries (LMICs) in sub-Saharan Africa, with inequitable distribution both between and within countries.2 Key quality-of-care implementation gaps have hampered the effectiveness of the World Health Organization (WHO) Integrated Management of Childhood Illnesses (IMCI) guidelines used for pediatric LRI care in LMICs.3 Evaluations of Integrated Management of Childhood Illness (IMCI) guidelines have identified inadequate triaging and therefore results in a failure to identify children at higher risk of death. Interventions to improve the sensitivity and specificity of the IMCI approach in identifying severely ill children could improve outcomes. Routine use of pulse oximetry, to non-invasively measure peripheral oxyhemoglobin saturation (SpO2), is poorly implemented at the primary healthcare (PHC) levels in LMICs, and therefore provides one such opportunity to improve IMCI assessments.

Hypoxemia - a low SpO2, is associated with increased mortality in children with LRI(1).4 Hypoxemia prevalence amongst children with pneumonia in African contexts has been estimated at 28%, and in outpatient settings as 23%.5 As hypoxemia is a key mortality risk factor, effectively identifying these children early in the care-seeking pathway is fundamental to reducing mortality in low-resource contexts.6 While SpO2 is recommended by IMCI for children with suspected pneumonia, pulse oximetry devices for measuring SpO2 are not widely implemented in PHCs in LMICs, where most children first access care. In Malawi 16% of nearly 700 outpatient encounters with suspected LRI had a SpO2 measured, and >40% of children eligible for hospitalization were not referred. Since few children have SpO2 collected during outpatient care, referral decisions are largely based on subjective clinical danger signs. This then has knock-on effects on receipt of oxygen treatment.

While pulse oximetry implementation in PHCs has been slow to scale-up, there is evidence of utility and feasibility. In Malawi, healthcare workers successfully measured the SpO2 on 94% of >14,000 children and were >2 times more likely to correctly refer a child when the child's SpO2 was low. This work also demonstrated >60% of hypoxemic children would not have been referred in the absence of an SpO2 measurement.7 One explanation for slow adoption is the lack of appropriate devices, that have been designed specifically for spot-checks amongst children in outpatient LMIC settings - a population with specific oximetry needs. Important features of such a device are being low cost, robust, able to cope with poor perfusion and motion artefact, good battery life and reliable.8

Mobile phones are relatively inexpensive, widely available, and increasingly utilized for healthcare - 'mobile Health (mHealth)', while electronic Health (eHealth) is when electronic services - like the internet - support healthcare. In LMICs mobile phones offer the potential for expanded healthcare access and quality of care both as a medical device and as a platform for eHealth services, such as the digital health management information system (HMIS) used in sub-Saharan Africa - District Health Information Software 2 (DHIS2). Developing a mobile-based pulse oximeter, with interoperability to store and upload data directly into a patients DHIS2 record has the potential to improve the management of paediatric hypoxaemia. The Phefumela Project, meaning "breathe" in a local South African language, will evaluate the impact of two different novel paediatric pulse oximeters, both designed specifically for this population in a high burden setting in South Africa.

Aim 1: Determine the impact of two novel paediatric pulse oximeter devices on the correct management of hypoxaemia.

Aim 2: Describe the burden of hypoxaemia and risks for mortality amongst children presenting with acute respiratory infections in a low-resource setting in Cape Town.

Setting:

The study site is the large Khayelitsha community, which includes 6 primary healthcare clinics (PHCs), 2 community health centers (CHCs), 1 community day centers (CDCs) and one government district hospital serving its catchment area, Khayelitsha Hospital. The nearest tertiary referral government hospital is Tygerberg, which serves 40% of the provincial paediatric population. Khayelitsha township has a population of approximately 450,000 and is 90.5% Black African. Khayelitsha has a very young population, with >40% of its residents under 19 years of age, residing in informal housing with high caregiver unemployment and limited running water access. HIV (human immunodeficiency virus) and tuberculosis prevalence is high; maternal HIV prevalence is 29.5% - the highest in the Western Cape Province - and the tuberculosis incidence of 1,389/100,000 population exceeded the national average of 834/100,000 in 2017.9 Khayelitsha Hospital has an average bed occupancy rate over 130% capacity, and its 47 bed emergency center cares for about 120 patients daily. A 2015 study characterized the pediatric case mix over six months at the emergency center, reporting >80% of pediatric patients were <5 years old, nearly 2/3 were triaged at an emergent level, and the most common diagnosis was LRIs (22.0%, n=70/317). Of 58 children with pneumonia, 5 (8.5%) died.9

Pulse oximeter devices:

The investigators will be using and comparing three different pulse oximeter devices during this study, two (the Phefumla and Lifebox-01 (LB-01) are not commercially available. The Contec device is widely available and currently used clinically in this setting in South Africa. Throughout this study, the Contec device will be considered the reference or control standard.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 0 to <24 months of age inclusive
  • presenting to care for an acute condition the includes observed and/or caregiver history of either cough and/or difficult breathing
  • residing in clinic catchment area
  • caregiver agrees to provide contact details including phone number and/or residential address
  • caregiver agrees to be contacted after two weeks by the study staff
  • caregiver is able and willing to provide written informed consent

Exclusion criteria

  • 24 months of age or older
  • presenting to care for a non-acute condition or an acute condition that does not include either observed or caregiver history of cough and/or difficult breathing
  • does not reside in the clinic catchment area
  • caregiver does not agree to provide contact details
  • caregiver does not agree to be contact by study staff after two weeks
  • caregiver unable to provide written informed consent

Treatment and study plan

Phefumla device

Device

The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.

LB-01 device

Device

The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.

Primary outcomes

  1. Proportion of Children with Correct management of oxygen saturation

    Time frame: Day 1

    The proportion of children aged 0 to <24 months with acute respiratory infection and (1) a HCW-documented SpO2 and heart rate measured in room air (i.e., off of supplemental oxygen), and (2) an appropriate referral recommendation has been provided by the HCW according to WHO-defined hypoxaemia status (SpO2 <90% or >90%) and (3) SpO2 confirmed by study staff measurement with reference device (within 2% SpO2 range above or below the documented SpO2).

Secondary outcomes

  1. Proportion of Children with Correct SpO2 management (definition 2)

    Time frame: Day 1

    The proportion of children aged 0 to <24 months with acute respiratory infection and (1) a SpO2 and heart rate measured in room air (i.e., off of supplemental oxygen) determined by verbal confirmation with child's caregiver and an (2) appropriate referral recommendation has been provided by the healthcare worker (HCW) according to WHO-defined hypoxaemia status (SpO2 <90% or >90%) as (3) determined by study staff measurement with reference device.

  2. Proportion of Children with Correct SpO2 management (definition 3)

    Time frame: Day 1

    The proportion of children aged 0 to <24 months with acute respiratory infection and (1) a HCW-documented SpO2 and heart rate measured in room air (i.e., off of supplemental oxygen), and (2) an appropriate referral recommendation has been provided by the HCW according to WHO-defined hypoxaemia status (SpO2 <90% or >90%) and (3) SpO2 confirmed by study staff measurement with the device assigned to arm (within 2% SpO2 range above or below the documented SpO2).

  3. Proportion of Children with Correct SpO2 management (definition 4)

    Time frame: Day 1

    The proportion of children aged 0 to <24 months with acute respiratory infection and (1) a SpO2 and heart rate measured in room air (i.e., off of supplemental oxygen) determined by verbal confirmation with child's caregiver and an (2) appropriate referral recommendation has been provided by the healthcare worker (HCW) according to WHO-defined hypoxaemia status (SpO2 <90% or >90%) as (3) determined by study staff measurement with the device assigned to arm.

  4. Proportion of Children with Correct SpO2 management (definition 5)

    Time frame: Day 1

    The proportion of children aged 0 to <24 months with acute respiratory infection and (1) a HCW-documented SpO2 and heart rate measured in room air (i.e., off of supplemental oxygen), and (2) an appropriate referral recommendation has been provided by the HCW according to WHO-defined hypoxaemia status (SpO2 <90% or >90%) and (3) hypoxemia status confirmed by study staff measurement with reference device (either hypoxemic or not hypoxemic).

  5. Proportion of Children with Correct SpO2 management (definition 6)

    Time frame: Day 15 after enrollment

    The proportion of children aged 0 to <24 months with acute respiratory infection and (1) a HCW-documented SpO2 and heart rate measured in room air (i.e., off of supplemental oxygen), and (2) an appropriate referral recommendation has been provided by the HCW according to WHO-defined hypoxaemia status (SpO2 <90% or >90%) and (3) hypoxemia status confirmed by study staff measurement with device assigned to arm (either hypoxemic or not hypoxemic).

  6. Communication fidelity as assessed by number of participants who had timely communication

    Time frame: Day 1

    The timely communication between 1) clinic and referral hospital (on day 1), and 2) clinic and caregiver (on day 1)

  7. Proportion of plausible measurement (Quality measurement)

    Time frame: Day 1

    Proportion of biologically plausible measurements among all measurements attempted by study staff and HCWs (only done when directly observed) using the assigned pulse oximeter device per arm and reference device.

  8. Feasibility as assessed by number of measurement attempts

    Time frame: Day 1

    The number of measurement attempts required to achieve a biologically plausible SpO2 measurement by either study staff or HCWs (only done when directly observed)

  9. Measurement acceptance as assessed by the proportion of caregivers who permit Sp02 measurement

    Time frame: Day 1

    The proportion of caregivers who permit the study staff or HCWs (only done when directly observed) to measure the SpO2 on the child.

  10. Referral acceptance as assessed by proportion of children who present to hospital

    Time frame: Day 2

    Amongst WHO-defined hypoxemic children, the proportion of children who present to a hospital within 24 hours.

  11. Oxygen treatment as assessed by proportion of children who are given oxygen treatment

    Time frame: Day 2

    Amongst WHO-defined hypoxemic children, the proportion who of children who present to a hospital and are given oxygen treatment within 24 hours.

  12. Treatment failure as assessed by proportion of children still feeling sick

    Time frame: Day 15

    The proportion of enrolled children who reported still feeling sick or whose caregiver reported any of the following signs: cough at 14 days, difficult breathing at 14 days, or change in antibiotic treatment or re-admission to clinic/hospital anytime at or before two-weeks (14 days) post study enrollment as confirmed by phone or home visit.

  13. Hypoxemia prevalence

    Time frame: Day 1

    Among all enrolled children who completed the intake/first (clinic) visit and had a successful SpO2 measurement, those whose (1) SpO2<90% (WHO-defined) as well as those (2) <94% (study defined) and (3) 90-93% (moderate), whose measurement was within -/+2% of the reference device measurement.

  14. Mortality

    Time frame: Day 15

    Measured among all enrolled children who successfully completed two-week follow up and defined as the number of children who have died from any cause within 14 days of recruitment.

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • Baylor College of Medicine
  • Fogarty International Center of the National Institute of Health
  • Karolinska Institutet
  • Thrasher Research Fund
  • University of Stellenbosch

Registry information

Official study title

Evaluating Novel Pediatric Pulse Oximeters for Outpatient Child Pneumonia Care in Sub-Saharan Africa

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jun 22, 2023
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.